To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library.
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Men on active surveillance for prostate cancer who had a negative confirmatory biopsy experienced an 88% decreased risk of progression to treatment.
In a meta-analysis, the risk of infectious complications was 78% lower with fosfomycin trometamol versus fluoroquinolones in men undergoing TRUS-guided prostate biopsy.
In a single center study, asymptomatic bacteriuria resolved before prostate biopsy, without additional treatment.
Multiparametric magnetic resonance imaging in conjunction with transrectal ultrasound-guided biopsy improves discrimination between clinically significant and insignificant prostate tumors and can spare patients unnecessary biopsies.
Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.
The transperineal approach to prostate biopsy has recently been adopted at many centers as an alternative to TRUS-B.
Investigators who compared 4 active surveillance cohorts found that biennial prostate biopsies appear to be an acceptable alternative to annual biopsies.
Most common infection in prostate biopsy was E. coli, followed by mild bleeding.
